Drug Combinations in Breast Cancer Therapy

Fisusi, Funmilola A.; Akala, Emmanuel O.

doi:10.2174/2211738507666190122111224

Cited by 307 publications

(213 citation statements)

References 129 publications

(143 reference statements)

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…[12,13] Currently, many different strategies are adopted to manage the CPassociated adverse toxic effects such as application of Mesna (antioxidant) or alternative CP analogs and a combination low dose of CP with other anticancer drugs. [14][15][16] Nevertheless, these strategies lack effectiveness and are not suitable for a wide range of applications. [17] Therefore, there is an urgent need to search for an effective and suitable chemoprotective agent, which can reduce the toxic effects of CP and can upsurge its therapeutic uses.…”

mentioning

confidence: 99%

Nicotinamide attenuates cyclophosphamide‐induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis

Patwa

Khan

Jena

2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Cyclophosphamide (CP) is a widely used anticancer and immunosuppressant drug. Nevertheless, clinical utilization of CP is limited due to considerable adverse effects and toxicities. Nicotinamide (NMD) is a micronutrient and the effect of NMD against CPinduced hepatotoxicity is yet unexplored. The present study was designed to evaluate the chemoprotective effect of NMD against CP-induced hepatic injury in Sprague-Dawley rats. Hepatotoxicity was induced by the administration of CP (30 mg/kg/day) for 10 consecutive days by intraperitoneal injection. The chemoprotective effect of NMD treatment (200 mg/kg) against CP-induced hepatotoxicity was evaluated by the oxidative stress, liver function, histopathological changes, and DNA damage. NMD cotreatment significantly reduced CP-induced oxidative stress, histological changes, and apoptosis in the liver. The present study demonstrated that NMD treatment ameliorated CP-induced hepatic damage by improving the antioxidant system and reducing DNA damage. The present findings revealed that NMD supplementation might be useful to reduce CP-associated hepatotoxicity, and thereby can increase the therapeutic utility of CP.

show abstract

mentioning

confidence: 99%

Nicotinamide attenuates cyclophosphamide‐induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis

Patwa

Khan

Jena

2020

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…Multidrug-loaded NPs micellar formulation was also developed for the delivery of three drugs: paclitaxel, 17-AAG (Triolimus), and rapamycin. They were evaluated on MDA-MB-231 tumour-bearing mice [ 148 ]. Hypoxia promotes the invasiveness of tumour cells and chemoresistance.…”

Section: Cancer Therapymentioning

confidence: 99%

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

2020

View full text Add to dashboard Cite

Nanomaterials, such as nanoparticles, nanorods, nanosphere, nanoshells, and nanostars, are very commonly used in biomedical imaging and cancer therapy. They make excellent drug carriers, imaging contrast agents, photothermal agents, photoacoustic agents, and radiation dose enhancers, among other applications. Recent advances in nanotechnology have led to the use of nanomaterials in many areas of functional imaging, cancer therapy, and synergistic combinational platforms. This review will systematically explore various applications of nanomaterials in biomedical imaging and cancer therapy. The medical imaging modalities include magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computerized tomography, optical imaging, ultrasound, and photoacoustic imaging. Various cancer therapeutic methods will also be included, including photothermal therapy, photodynamic therapy, chemotherapy, and immunotherapy. This review also covers theranostics, which use the same agent in diagnosis and therapy. This includes recent advances in multimodality imaging, image-guided therapy, and combination therapy. We found that the continuous advances of synthesis and design of novel nanomaterials will enhance the future development of medical imaging and cancer therapy. However, more resources should be available to examine side effects and cell toxicity when using nanomaterials in humans.

show abstract

“…Among these, chemotherapy is routinely administered to early-stage breast cancer patients as adjuvant therapy to reduce tumour size or cancer recurrence before and after mastectomy. Representative chemicals currently used to treat early breast cancer include doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, carboplatin fluorouracil and epirubicin [ 4 , 5 ]. Various combinations of these chemicals are generally recommended for early-stage breast cancer patients and play an important role in the direction of tumour treatment and patient survival.…”

Section: Introductionmentioning

confidence: 99%

A novel radiolytic rotenone derivative, rotenoisin A, displays potent anticarcinogenic activity in breast cancer cells

Bak

Kang

Park

et al. 2021

Journal of Radiation Research

View full text Add to dashboard Cite

Chemotherapy for cancer treatment has therapeutic limitations, such as drug resistance, excessive toxic effects and undesirable adverse effects. Therefore, efforts to improve the safety and efficacy of chemotherapeutic agents are essential. Ionizing radiation can improve physiological and pharmacological properties by transforming structural modifications of the drug. In this study, in order to reduce the adverse effects of rotenone and increase anticancer activity, a new radiolytic rotenone derivative called rotenoisin A was generated through radiolytic transformation. Our findings showed that rotenoisin A inhibited the proliferation of breast cancer cells and increased the rate of apoptosis, whereas it had no inhibitory effect on primary epidermal keratinocytes compared with rotenone. Moreover, rotenoisin A-induced DNA damage by increasing reactive oxygen species (ROS) accumulation. It was also confirmed not only to alter the composition ratio of mitochondrial proteins, but also to result in structural and functional changes. The anticancer effect and molecular signalling mechanisms of rotenoisin A were consistent with those of rotenone, as previously reported. Our study suggests that radiolytic transformation of highly toxic compounds may be an alternative strategy for maintaining anticancer effects and reducing the toxicity of the parent compound.

show abstract

Drug Combinations in Breast Cancer Therapy

Cited by 307 publications

References 129 publications

Nicotinamide attenuates cyclophosphamide‐induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis

Nicotinamide attenuates cyclophosphamide‐induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

A novel radiolytic rotenone derivative, rotenoisin A, displays potent anticarcinogenic activity in breast cancer cells

Contact Info

Product

Resources

About